Current Issue 28 August 2012, Vol. 321, No. 2

Issue Highlights

Mini-reviews

Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
28 August 2012(Vol. 321 | No. 2 | Pages 101-109)
Karen L. Reckamp

Mucins and Toll-like receptors: Kith and kin in infection and cancer
28 August 2012(Vol. 321 | No. 2 | Pages 110-119)
Shikha Tarang, Sushil Kumar, Surinder K. Batra

Regular Articles

Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells
28 August 2012(Vol. 321 | No. 2 | Pages 120-127)
Adnan O. Abu-Yousif, Anne C.E. Moor, Xiang Zheng, Mark D. Savellano, Weiping Yu, Pål K. Selbo, Tayyaba Hasan

Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance
22 May 2012
Akihiro Murakami, Kazuyuki Yakabe, Keiko Yoshidomi, Kotaro Sueoka, Shugo Nawata, Yoshihito Yokoyama, Shigeki Tsuchida, Fahd Al-Mulla, Norihiro Sugino
Abstract: Human carbonyl reductase 1 (CBR1) is an enzyme that catalyse the reduction of many compounds by using NADPH-dependent oxydoreductase activity. Although CBR1 is known to regulate the tumour p...
Oxidatively generated complex DNA damage: Tandem and clustered lesions
21 May 2012
Jean Cadet, Jean-Luc Ravanat, Marisa TavernaPorro, Hervé Menoni, Dimitar Angelov
Abstract: There is an increasing interest for oxidatively generated complex lesions that are potentially more detrimental than single oxidized nucleobases. In this survey, the recently available infor...
miR-409-3p inhibits HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin
21 May 2012
Chunhua Weng, Haojie Dong, Guangdi Chen, Yixing Zhai, Rongpan Bai, Hu Hu, Linrong Lu, Zhengping Xu
Abstract: Although the expression of angiogenin (ANG), an angiogenic and tumorigenic factor, is elevated in various types of cancers, its regulation mechanism remains unclear. In the present study, in...
Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells
21 May 2012
Saar Shapira, Galit Granot, Rahav Mor-Tzuntz, Pia Raanani, Orit Uziel, Meir Lahav, Ofer Shpilberg
Abstract: In this study we present the effects of nilotinib and dasatinib on telomerase activity and regulation. Nilotinib and dasatinib strongly reduced telomerase activity in BCR-ABL-positive (K562)...
Breast cancer stem cells: Obstacles to therapy
21 May 2012
Matthew Smalley, Luke Piggott, Richard Clarkson
Abstract: Only a fraction of the cells in a breast tumour are able to seed new tumour growth. These so-called breast cancer stem cells (bCSCs) are characterised by a number of discrete functional prop...

View More Articles in Press...

On the Cover

New Issue Alert

Free Trial Issue

Journal Ranking

Impact Factor: 4.864

Journal Access

Full-text articles are available from 1995 to the present. Access to abstracts is complimentary. Access to full text is limited to print subscribers. Register or login to:

Activate Online Access

Publishing Information

Cancer Letters is published by Elsevier.

Access this journal onSciVerse ScienceDirect

About Cancer Letters

Cancer Letters is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and translational oncology. Additionally, Special Issues highlight topical areas in cancer research. Basic areas of interest to a broad readership of Cancer Letters include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal places emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine.